Braintree Laboratories, Inc.
about usproductsnews and eventshomesite mapcontact us



news and events
News:

 

October, 2009     Braintree Laboratories, Inc. and Ipsen: Ipsen acquires exclusive marketing rights in selected ex-U.S. territories of BLI-800 from Braintree Laboratories, Inc for colonic cleansing before colonoscopy (pdf: press release click here)
September, 2007     Approval of 10 mg HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) With Flavor Packs
December, 2006   Schering-Plough Corporation and Braintree Laboratories, Inc. have entered an agreement which gives Schering Plough the rights to market MiraLAX® (polyethylene glycol 3350) as a nonprescription treatment for occasional constipation.
October, 2006    MiraLAX (Polyethylene Glycol 3350, NF Powder) approved for over the counter use by the United States Food and Drug Administration.
June, 2005    Braintree Laboratories, Inc. announces the acquisition of Axid (nizatidine) Oral Solution from Reliant Pharmaceuticals
June, 2005   Approval by the United States Food and Drug Administration of HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets) With Flavor Packs
August, 2003   Braintree Laboratories, Inc. enters an agreement with Nabi Biopharmaceuticals which grants Nabi the worldwide rights to PhosLo® (Calcium Acetate)
June, 2003

 

  Approval by the United States Food and Drug Administration of NuLYTELY® (PEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution) With Flavor Packs
December, 2001

 

  Braintree Laboratories, Inc. and its employees present the firefighters of New York City with a brand new state-of-the-art Seagrave Tower Ladder Truck - FDNY Ladder Co. 107
April, 2001

 

  Approval by the United States Food and Drug Administration of PhosLo® GelCaps (Calcium Acetate) 667 mg
February, 1999

 

  Approval by the United States Food and Drug Administration of MiraLax® (Polyethylene Glycol 3350, NF Powder)
April, 1991

 

  Approval by the United States Food and Drug Administration of  NuLYTELY® (PEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution)
December, 1990

 

  Approval by the United States Food and Drug Administration of PhosLo® (Calcium Acetate tablets) 667mg
July, 1984  Approval by the United States Food and Drug Administration of the first oral lavage solution, GoLYTELY® (PEG-3350 and Electrolytes for Oral Solution)



Compliance   CA Health and Safety Code

Braintree Laboratories, Inc. © 2002 --- Created by PixelMEDIA, Inc.